Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Inclusion Criteria: 1. Written informed consent signed; 2. Age ≤75 years; 3. Clinically or multidisciplinary diagnosed idiopathic pulmonary fibrosis(see 2011 guidance ); 4. Resting state PaO2≥50mg, FVC%≥45% normal predicted value and DLCO≥30% normal predicted value. Exclusion Criteria: 1. Allergic to pirfenidone; 2. Patients with serious Significant pulmonary infection need anti-infection treatment; 3. Patients who has taken interferon, penicillamine or other agents for the treatment of IPF; 4. Patients who has taken prednisone(≥50mg) or other glucocorticoid in the past 1 month; 5. Patients who has taken immunosuppressants in the past 1 month; 6. Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3 months; 7. Patients with malignant tumor in the past 5 years; 8. Participated in other clinical trials in the past 3 months; 9. Patients with serious heart disease(NYHA class Ⅲ-Ⅳ), liver disease(ALT or AST 2 times above the upper level of normal value range), kidney disease(Cr above the upper level of normal value range); 10. Pregnant or lactating women; 11. The investigator assessed as inappropriate to participate in this clinical trial.